Calamos Advisors LLC Reduced Holding in Stryker Co. (NYSE:SYK)

Calamos Advisors LLC Reduced Holding in Stryker Co. (NYSE:SYK)

Calamos Advisors LLC lowered its stake in Stryker Co. (NYSE:SYK) by 18.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 95,841 shares of the medical technology company’s stock after selling 21,572 shares during the period. Calamos Advisors LLC’s holdings in Stryker were worth $15,023,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Northwest Wealth Management LLC lifted its holdings in Stryker by 103.6% during the 4th quarter. Northwest Wealth Management LLC now owns 169 shares of the medical technology company’s stock worth $26,000 after purchasing an additional 86 shares in the last quarter. Horan Securities Inc. purchased a new stake in shares of Stryker in the 4th quarter valued at about $30,000. Moody National Bank Trust Division purchased a new stake in shares of Stryker in the 4th quarter valued at about $32,000. Cornerstone Advisors Inc. raised its holdings in shares of Stryker by 17.4% in the 3rd quarter. Cornerstone Advisors Inc. now owns 485 shares of the medical technology company’s stock valued at $86,000 after acquiring an additional 72 shares in the last quarter. Finally, Legacy Financial Advisors Inc. raised its holdings in shares of Stryker by 108.1% in the 4th quarter. Legacy Financial Advisors Inc. now owns 645 shares of the medical technology company’s stock valued at $101,000 after acquiring an additional 335 shares in the last quarter. Institutional investors own 73.38% of the company’s stock.

Several equities analysts have recently commented on the company. Barclays assumed coverage on Stryker in a research report on Monday, October 15th. They set an “overweight” rating and a $198.00 price objective on the stock. Oppenheimer set a $170.00 price objective on Stryker and gave the company a “hold” rating in a research report on Friday, October 26th. Zacks Investment Research upgraded Stryker from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research report on Tuesday, October 30th. Needham & Company LLC restated a “hold” rating on shares of Stryker in a research report on Friday, November 9th. Finally, Cowen set a $195.00 price objective on Stryker and gave the stock a “buy” rating in a research report on Friday, November 9th. Seven investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $185.37.

NYSE:SYK opened at $182.66 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $67.62 billion, a P/E ratio of 24.99, a PEG ratio of 2.22 and a beta of 0.86. Stryker Co. has a 12 month low of $144.75 and a 12 month high of $182.69.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.15 by $0.03. The business had revenue of $3.80 billion for the quarter, compared to the consensus estimate of $3.73 billion. Stryker had a return on equity of 29.21% and a net margin of 26.12%. On average, equities research analysts anticipate that Stryker Co. will post 8.12 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, March 28th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 1.14%. Stryker’s dividend payout ratio is 28.45%.

In other news, VP Michael Damon Hutchinson sold 15,995 shares of the stock in a transaction on Friday, February 8th. The stock was sold at an average price of $180.49, for a total transaction of $2,886,937.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP M Kathryn Fink sold 180 shares of the firm’s stock in a transaction on Monday, February 4th. The stock was sold at an average price of $176.77, for a total value of $31,818.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,259 shares of company stock worth $7,515,747. Insiders own 7.30% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Article: Insider Trading

Related posts

Leave a Comment